Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy
Joint Authors
Drazilova, Sylvia
Janicko, Martin
Jarcuska, Peter
Gazda, Jakub
Source
Canadian Journal of Gastroenterology and Hepatology
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-08-13
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Patients with chronic hepatitis C have both higher prevalence of diabetes mellitus type 2 (T2DM) and increased cardiovascular risk compared to never infected people.
Sustained viral response (SVR) achievement led to decreasing incidence and prevalence of T2DM during the interferon era of HCV treatment.
Currently, direct-acting antiviral drugs (DAA) are the gold standard for treating HCV infection, while yielding SVR in nearly all patients.
In chronic HCV patients with T2DM (prediabetes most likely too), DAA therapy is associated with both better fasting glucose and glycated hemoglobin (HbA1C) controls; thus reducing pharmacotherapy in a certain part of patients is possible.
Papers mentioned in the review confirmed DAA role in both total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) increase.
This alteration was accompanied by an increase in high-density lipoprotein cholesterol (HDL-C) and a decrease in triglycerides (TG) verified by most of the studies.
However, the clinical significance of lipoprotein alterations caused by DAA therapy has not been explained yet.
Moreover, DAA treatment of chronic hepatitis C improves hypertension control and atherosclerotic plaques.
It is very likely that DAA therapeutic regimens will decrease both T2DM prevalence and cardiovascular risk in chronic hepatitis C patients; further research, however, is needed.
American Psychological Association (APA)
Drazilova, Sylvia& Gazda, Jakub& Janicko, Martin& Jarcuska, Peter. 2018. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Canadian Journal of Gastroenterology and Hepatology،Vol. 2018, no. 2018, pp.1-11.
https://search.emarefa.net/detail/BIM-1130988
Modern Language Association (MLA)
Drazilova, Sylvia…[et al.]. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Canadian Journal of Gastroenterology and Hepatology No. 2018 (2018), pp.1-11.
https://search.emarefa.net/detail/BIM-1130988
American Medical Association (AMA)
Drazilova, Sylvia& Gazda, Jakub& Janicko, Martin& Jarcuska, Peter. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Canadian Journal of Gastroenterology and Hepatology. 2018. Vol. 2018, no. 2018, pp.1-11.
https://search.emarefa.net/detail/BIM-1130988
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1130988